Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: A cDNA and tissue microarray study

Clinical Cancer Research

Volumn 9, Issue 1 I, 2003, Pages 68-75

  Wasenius, Veli Matti ^a   Hemmer, Samuli ^a   Kettunen, Eeva ^b   Knuutila, Sakari ^b   Franssila, Kaarle ^a   Joensuu, Heikki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CGD PROTEIN; COMPLEMENTARY DNA; CYSTEINE RICH PROTEIN 61; DLG3 PROTEIN; FC RECEPTOR; FIBRONECTIN; GLYCINE TRANSFER RNA LIGASE; GRAVIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HBA1 PROTEIN; HETEROCHROMATIN PROTEIN 1 HOMOLOGUE ALPHA; HLA D ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1; LACTATE DEHYDROGENASE ISOENZYME; MACROPHAGE INHIBITORY CYTOKINE 1; POLYCYSTIC KIDNEY DISEASE 1 PROTEIN; PROTEIN; PROTEIN TYROSINE PHOSPHATASE; SCATTER FACTOR RECEPTOR; SMAD4 PROTEIN; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DNA MICROARRAY; GENE; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID PAPILLARY CARCINOMA; VALIDATION PROCESS;

CARCINOMA, PAPILLARY; DNA, COMPLEMENTARY; DOWN-REGULATION; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MATRIX METALLOPROTEINASE 11; METALLOENDOPEPTIDASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-MET; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; UP-REGULATION;

EID: 0037242227     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Schlumberger, M. J. Papillary and follicular thyroid carcinoma. N. Engl. J. Med., 338: 297-306, 1998.
2. Harach, H. R., Franssila, K. F., and Wasenius, V-M. Occult papillary carcinoma of the thyroid-a normal finding in Finland-a systematic autopsy study. Cancer. 56: 531-538, 1985.
3. Roque, L., Clode, A. L., Gomes, P., Rosa-Santos, J., Soares, J., and Castedo, S. Cytogenetic findings in 31 papillary thyroid carcinomas. Genes Chromosomes Cancer. 13: 157-162, 1995.
4. Hemmer, S., Wasenius, V-M., Knuutila, S., Franssila, K., and Joensuu, H. DNA copy number changes in thyroid carcinoma. Am. J. Pathol., 154: 1539-1547, 1999.
5. Singh, B., Lim, D., Cigudosa, J. C., Ghossein, R., Shaha, A. R., Poluri, A., Wreesmann, V. B., Tuttle, M., Shah, J. P., and Rao, P. H. Screening for genetic aberrations in papillary thyroid cancer by using comparative genomic hybridization. Surgery, 128: 888-894, 2000.
6. Kjellman, P., Lagercrantz. S., Höög, A., Wallin, G., Larsson, C., and Zedenius, J. Gain of 1q and loss of 9q21.3-q32 are associated with a less favorable prognosis in papillary carcinoma. Genes Chromosomes Cancer, 32: 43-49, 2001.
7. Grieco, M., Santoro, M., Berlingieri, M. T., Melillo, R. M., Donghi, R., Bongarzone, I., Pierotti, M. A., Dell Porta, G., Fusco, A., and Vecchio, G. PTC is a novel rearranged form of ret proto-oncogene and frequently detected in vivo in human thyroid papillary carcinomas. Cell, 60: 557-563, 1990.
8. Di Renzo, M. F., Narsimhan, R. P., Olivero, M., Bretti, S., Giordano, S., Medico, E., Gaglia, P., Zara, P., and Comoglio, P. M. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene, 6: 1997-2003, 1991.
9. Di Renzo, M. F., Olivero, M., Ferro, S., Prat, M., Bongarzone, I., Pilotti, S., Belfiore, A., Constantino. A., Vogneri, R., Pierotti, M. A., and Comoglio, P. M. Overexpression of the c-MET/HGF receptor in human thyroid carcinomas. Oncogene, 7: 2549-2553, 1992.
10. Chen, C. B., Ohtsuki, Y., Furihata, M., Takeuchi, T., Iwata, J., Liang, S. B., and Sonobe, H. Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathological stage. Pathol. Res. Pract., 195: 427-433, 1999.
11. Scarpino, S., Stoppacciaro, A., Colarossi, C., Cancellario, F., Marzullo, A., Marchesi, M., Biffoni, M., Comoglio, P. M., Prat, M., and Ruco, L. P. Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary thyroid carcinoma of the thyroid. J. Pathol., 189: 570-575, 1999.
12. Fluge, O., Haugen, D. R., Lillehaug, J. R., and Varhaug, J. E. Difference in patterns of Met expression in papillary thyroid carcinomas and nonneoplastic thyroid tissue. World J. Surg., 25: 623-631, 2001.
13. Ippolito, A., Vella, V., La Rosa, G. L., Pellegriti, G., Vigneri, R., and Belfiore, A. Immunostaining for Met/HGF receptor may be useful to identify malignancies in thyroid lesions classified suspicious at fine needle aspiration biopsy. Thyroid, 11: 783-787, 2001.
14. Ramirez, R., Hsu, D., Patel, A., Fenton, C., Dinauer, C., Turtle, R. M., and Francis, G. L. Over-expression of hepatocyte growth factor/ scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin. Endocrinol., 53: 635-644, 2000.
15. Ryu, S., Jimi, S., Eura, Y., Kato, T., and Takebayashi, S. Strong intracellular and negative peripheral expression of fibronectin in tumor cells contribute to invasion and metastasis in papillary thyroid carcinoma. Cancer Lett., 146: 103-109, 1999.
16. Takano, T., Miyauchi, A., Yokozawa, T., Matzuzuka, F., Maeda, I., Kuma, K., and Amino, N. Preoperative diagnosis of thyroid papillary and anaplastic carcinomas by real-time quantitative reverse transcription-PCR of oncofoetal fibronectin messenger RNA. Cancer Res., 59: 4542-4545, 1999.
17. Takano, T., Shiba, E., Tada, H., Yoshimura, H., Yoshida, K., Doi, R., and Amino, N. Preoperative diagnosis of thyroid carcinomas by aspiration biopsy-reverse transcription-polymerase chain reaction (ABRP): a report of two cases. Endocr. J., 47: 271-275, 2000.
18. Kononen, J., Bubendorf, L., Kallioniemi, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O-P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med., 4: 844-847, 1998.
19. Gmyrek, G. A., Walburg, M., Webb, C. P., Yu, H-M., You, X., Vaughan, E. D., Vande Woude, G. F., and Knudsen, B. S. Normal and malignant prostate epithelial cells differ in their response to hepacyte growth factor/scatter factor. Am. J. Pathol., 159: 579-590, 2001.
20. Duffy, M. J., Maguire, T. M., Hill, A., Mcdermott, E., and O'Higgins, N. Metalloproteinases. Role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res., 2: 252-257, 2000.
21. Delebecq, T. J., Porte, H., Zerimech, F., Copin, M. C., Gouyer, V., Dacquembronne, E., Balduyck, M., Wurtz, A., and Huet, G. Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. Clin. Cancer Res., 6: 1086-1092, 2000.
22. Jin, L., Fuchs, A., Schnitt, S., Yao, Y., Joseph, A., Lamszus, K., Park, M., Goldberg, I. D., and Rosen, E. M: Expression of scatter factor and c-met rexeptor in benign and malignant breast tissue. Cancer (Phila.), 79: 749-760, 1997.
23. Tapper, J., Kettunen, E., El-Rifai, W., Seppälä, M., Andersson, L. C., and Knuutila, S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet. Cytogenet., 128: 1-6, 2001.
24. Frasca, F., Vigneri, P., Vella, V., Vigneri, R., and Wang, J. Y. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor. Oncogene, 20: 3845-3856, 2001.
25. Boulay, A., Masson, R., Chenard, M-P., El Fahime, M., Cassard, L., Bellocq, J-P., Sautés-Fridman, C., Basset, P., and Rio, M-C. High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res., 61: 2189-2193, 2001.
26. Shi, Y., Parhar, R. S., Zou, M., Hammami, M. M., Akhtar, M., Lum, Z. P., Farid, N. R., Al-Sedairy, S. T., and Paterson, M. C. Tissue inhibitor of metalloproteinases-1 (TIMP-1) mRNA is elevated in advanged stages of thyroid carcinoma. Br. J. Cancer, 79: 1234-1239, 1999.
27. Maeta, H., Ohgi, S., and Terada, T. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch., 438: 121-128, 2001.
28. de la Fuente, M. T., Casanova, B., Garcia-Gila, M., Silva, A., and Garcia-Pardo, A. Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronoc lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia (Baltimore), 13: 266-274, 1999.
29. Danen, E. H., and Yamada, K. M. Fibronectin, integrins, and growth control. J. Cell. Physiol., 189: 1-13, 2001.
30. Takayasu, H., Horie, H., Hiyama, E., Matsunaga, T., Hayashi, Y., Watanabe, Y., Suita, S., Kaneko, M., Sasaki, F., Hashizume, K., Ozaki, T., Furuuchi, K., Tada, M., Ohnuma, N., and Nagakawara, A. Frequent deletions and mutations of the β-catenin are associated with overexpression of cyclin D 1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin. Cancer Res., 7: 901-908, 2001.
31. Sallinen, S-L., Sallinen, P. K., Haapasalo, H. K., Helin, H. J., Helén, P. T., Schraml, P., Kallioniemi, O-P., and Kononen, J. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res., 60: 6617-6622, 2000.
32. Wolf, M., El-Rifai, W., Tarkkanen, M., Kononen, J., Serra, M., Eriksen, E. F., Elomaa, I., Kallioniemi, A., Kallioniemi, O-P., and Knuutila, S. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genet. Cytogenet., 123: 128-132, 2000.
33. Inufusa, H., Nakamura, M., Adachi, T., Nakatani, Y., Shindo, K., Yasutomi, M., and Matsuura, H. Localization of oncofetal and normal fibronectin in colorectal cancer. Cancer (Phila.), 75: 2802-2808, 1995.
34. Takano, T., Hasewaga, Y., Matsuzuka, F., Miyauchi, A., Yoshida, H., Higashiyama, T., Kuma, K., and Amino, N. Gene expression profiles in thyroid carcinomas. Br. J. Cancer, 83: 1495-1502, 2000.
35. Takano, T., Miyauchi, A., Matsuzuka, F., Kuma, K., and Amino, N. Expression of oncofetal fibronectin messenger ribonucleic acid in fibroblasts in the thyroid: a possible cause of false positive results in molecular-based diagnosis of thyroid carcinomas. J. Clin. Endocrinol. Metab., 85: 765-768, 2000.
36. Huang, H., Colella, S., Kurrer, M., Yonekawa, Y., Kleihues, P., and Ohgaki, H. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res., 60: 6868-6874, 2000.
37. Lassus, H., Salovaara, R., Aaltonen, L., and Butzow, R. Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4. SMAD2, and DCC. Am. J. Pathol., 159: 35-41, 2001.
38. Duff, E. K., and Clarke, A. R. Smad4 (DPC4)-a potent tumour suppressor? Br. J. Cancer, 78: 1615-1619, 1998.
39. Jones, A., Fujiyama, C., Blanche, C., Moore, J. W., Fuggle, S., Cranston, D., Bicknell, R., and Harris, A. L. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α in human bladder tumors and cell lines. Clin. Cancer Res., 7: 1263-1272, 2001.
40. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs, W. B., Semenza, G. L., and Simons, J. W. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res., 59: 5830-5835, 1999.
41. Bos, R., Zhong, H., Hanrahan, C. F., Mommers, E. C., Semenza, G. L., Pinedo, H. M., Abeloff, M. D., Simons, J. W., van Diest, P. J., and van der Wall, E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J. Natl. Cancer Inst. (Bethesda), 93: 309-314, 2001.
42. Maytin, E. V., Ubeda, M., Lin, J. C., and Habener, J. F. Stress-inducible transcription factor CHOP/gadd153 induces apoptosis in mammalian cells via p38 kinase-dependent and -independent mechanisms. Exp. Cell Res., 267: 193-204, 2001.
43. Chen, K-T., Lin, J-D., Chao, T-C., Hsueh, C., Chang, C. A., Weng, H-F., and Chan, E-C. Identification differentially expressed genes associated with metastasis of follicular thyroid cancer by cDNA expression array. Thyroid, 11: 41-46, 2001.
44. Patino, P. J., Perez, J. E., lopez, J. A., Condino-Neto, A., Grumach, A. S., Botero, J. H., Curnutte, J. T., and Garcia de Olarte, D. Molecular analysis of chronic granulomatous disease caused by defects in gp91-phox. Hum. Mutat., 13: 29-37, 1999.
45. Brocksedt, E., Rickers, A., Kostka, S., Laubersheimer, A., Dörken, B., Wittmann-Liebold, B., Bommert, K., and Otto, A. Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line. J. Biol. Chem., 43: 28057-28064, 1998.
46. Welsh, J. B., Sapinoso, L. M., Su, A. I., Kern, S. G., Wang-Rodriquez, J., Moskaluk, C. A., Frierson, H. F., and Hampton, G. M. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res., 61: 5974-5978, 2001.
47. Xu, L., Hui, L., Wang, S., Gong, J., Wang, Y., Ji, Y., Wu, X., Han, Z., and Hu, G. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res., 61: 3176-3181, 2001.
48. Xia, W., Unger, P., Miller, L., Nelson, J., and Gelman, I. H. The scr-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res., 61: 5644-5651, 2001.